[Pharmacokinetic and clinical studies of ceftizoxime in obstetrical and gynecological field (2)].
Pharmacokinetic and clinical evaluations of ceftizoxime (CZX) in 3 obstetrical and gynecological clinics have substantiated the therapeutic usefulness of this drug in the relevant specialty. The results are summarized below. 1. The peak serum CZX concentration after drip infusion of 2 g given over 60 minutes was 115.3 micrograms/ml. The peak CZX concentration in the pelvic dead space exudate was 34.10 micrograms/ml which was attained 2.02 hours after beginning infusion. Half-lives of CZX in the serum and in the pelvic dead space exudate were 1.64 hours and 3.65 hours, respectively. 2. The passage of infused CZX to the umbilical cord serum was satisfactorily rapid, as evidenced by figures reaching 10 micrograms/ml or higher at 1 hour and 15 minutes and still as high as 3 micrograms/ml or higher at 6 hours after administration. 3. The passage of CZX to the milk of mothers receiving this drug was low, and no untoward effect on the infant was likely. 4. CZX would effectively prevent infections due to premature ruptures of membrane.
Ito
K
K
Department of Obstetrics and Gynecology, School of Medicine, Gifu University.
Izumi
K
K
Takagi
H
H
Yokoyama
Y
Y
Tamaya
T
T
Baba
Y
Y
Hayasaki
M
M
D000328:Adult; D001424:Bacterial Infections / Q000517:prevention & control*; D015296:Ceftizoxime / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D005312:Fetal Blood / Q000378:metabolism; D005322:Premature Rupture of Fetal Membranes / Q000150:complications; D006207:Half-Life; D006801:Humans; D007231:Infant, Newborn; D007262:Infusions, Intravenous; D008431:Maternal-Fetal Exchange; D008895:Milk, Human / Q000378:metabolism*; D011247:Pregnancy
D015296:Ceftizoxime